10.5 DEVELOPMENTAL FUNDS Developmental Funds are critical to the future progress of the OSUCCC. During the prior funding period, the OSUCCC benefited from $1,858,197 in CCSG developmental funds. For the $1,308,482 of CCSG dollars used for faculty recruitment, the return to date in total direct costs for CCSG-approved peer-reviewed extramural funding is $ 28,576,879 (22:1 return on investment), and in total funding was $72,421,123 (55:1 return on investment, Table 1). In addition, we used CCSG funds for establishment of two shared resources, the Microarray Shared Resource and the Real Time PCR Shared Resource. A brief summary of the progress with these two facilities is described below, because their operation as fully established shared resources is described elsewhere in this application. In the 1999 CCSG competing renewal, """"""""Developmental Funds"""""""" received a merit descriptor of """"""""excellent"""""""". It was noted that there was no letter of assurance from the University attesting to the statement that developmental funds would be matched on a 10:1 basis, nor was there a clear outline of just how or in what form the University funds would be provided in supplementing the developmental funds. There were additional concerns that the junior to mid-level positions to be recruited during the last two years of the grant period were inadequate in description. Finally, there were concerns that the recruitment of a research mammographer might not be possible without a more research-oriented climate in radiology. In the present application, we provide evidence that the University is now providing the new OSUCCC Director with over $9 M/year in funds, an increase of over $8.5 M/year since our last competitive renewal. These dollars are to be used entirely to continue to develop the cancer program at OSU and as such, are matching to any CCSG dollars provided for this purpose. Written assurance of this $9 M/year commitment from both the OSU President and the Senior Vice President for Health Sciences is provided in section 6.7 of Essential Characteristics. In the present application we have tried to provide a more complete description of all 11 faculty we intend to recruit with CCSG developmental funds. In response to the concerns of first establishing a research environment in imaging prior recruiting a research mammographer, we first invested in recruiting a world-class imaging researcher who has initiated the development of a palpable research program in radiology, now making it more suitable to pursue additional imaging investigators. We are requesting support for continued faculty recruitment and continued shared resource development. We propose to focus our recruitment on 11 new faculty: two in the area of cancer prevention and control, three in basic or translational aspects on solid tumor oncology (breast, gastrointestinal, and prostate), one faculty member for each of biostatistics, pathology and human imaging research and three basic researchers in human cancer genetics. We request CCSG funds to develop three new shared resources (SR): a small animal imaging SR, a pharmacoanalytical SR and a cancer biomedical informatics SR. Both our Internal and External Scientific Advisors believe that strategically directed recruitment and SR development are the two best ways to continue to use new developmental funds, given the success with these funds to date and the resultant growth of the OSUCCC over the past 4 years. In Section 10.5.2, we describe our request for developmental funds for the next funding period. Section 10.5.3 describes the resources available to the OSUCCC to supplement the requested `$1 M annually in developmental funds. Our request represents less than 25% of our total annual direct CCSG request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-32
Application #
7630211
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
32
Fiscal Year
2007
Total Cost
$870,774
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sharpnack, Michael F; Chen, Bin; Aran, Dvir et al. (2018) Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine 27:167-175
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314
Bassett, Emily A; Palanichamy, Kamalakannan; Pearson, Mitchell et al. (2018) Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. Oncotarget 9:14597-14607
Trn?ný, Marek; Verhoef, Gregor; Dyer, Martin Js et al. (2018) A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica 103:1351-1358
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Kim, Miriam Y; Yu, Kyung-Rok; Kenderian, Saad S et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell 173:1439-1453.e19
Malpeli, Giorgio; Barbi, Stefano; Tosadori, Gabriele et al. (2018) MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget 9:29753-29771
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Li, Jingyi; Xu, Jie; Abruzzo, Lynne V et al. (2018) Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6. Oncotarget 9:10987-10994

Showing the most recent 10 out of 2602 publications